INTRODUCTION {#S1}
============

Histological grades and cytological subtypes of hepatocellular carcinoma (HCC) have been established.^\[[@ref1]\]^ Previous studies suggest that high tumor grade is associated with tumor recurrence and decreased survival after orthotopic liver transplantation (OLT) among patients within Milan criteria and higher local tumor progression rates after radiofrequency ablation (RFA) among Barcelona clinic liver cancer (BCLC) Stage A patients.^\[[@ref2]-[@ref4]\]^ High tumor grade on explant is also associated with lack of odds ratio (OR) to transcatheter arterial chemoembolization (TACE).^\[[@ref5]\]^ In regard to cytological subtype, the clear-cell variant has been associated with improved survival after surgical resection^\[[@ref6]-[@ref8]\]^ though data conflicts.^\[[@ref9],[@ref10]\]^ However, aforementioned studies predominantly include patients with early-stage disease and are not fully reflective of HCC populations treated with locoregional therapy (LRT). Further, tumor grade on explant after LRT may differ from before therapy. There is also a paucity of literature on the prognostic value of cytological subtype in patients treated with LRT. This study was undertaken to assess the relationship between baseline histological features of HCC and clinical stage, computed tomographic (CT) and magnetic resonance imaging (MRI) features, and outcomes in patients treated with LRT.

SUBJECTS AND METHODS {#S2}
====================

Study cohort {#S2_1}
------------

This single-center retrospective cohort study was approved by our Institutional Review Board and in compliance with the Health Insurance Portability and Accountability Act, with a waiver of informed consent for retrospective review of medical records. Consecutive patients (*n* = 124, mean age 61 years; age range 30--85 years) at the University of Illinois Hospital with 132 percutaneous biopsy-proven HCC who subsequently underwent LRT were identified through retrospective chart review from 2008 to 2017. The cohort included 92 men with mean age of 59 years (range 30--85 years) and 32 women with mean age of 65 years (range 47--83 years). LRT modalities were transarterial chemoembolization (TACE, *n* = 51, 41%), percutaneous thermal ablation (*n* = 41, 33%), yttrium-90 (Y90) radioembolization (*n* = 17, 13%), and combination TACE/ablation (*n* = 15, 12%). Baseline BCLC stage was 0/A (*n* = 48, 38%), B (*n* = 33, 26%), C (*n* = 27, 22%), and D (*n* = 16, 13%). Mean tumor diameter was 4.8 cm ± 4.1 cm. The most common etiology of HCC was hepatitis C virus (38.7%). Ethnicity, gender, age, baseline laboratory values, Child-Pugh (CP) class, cirrhosis etiology, and type of LRT were tabulated \[[Table 1](#T1){ref-type="table"}\]. The mean time from biopsy to LRT was 34 days (standard deviation, 60 days).

###### 

Baseline demographic characteristics.

                                 *n* (%)
  ------------------------------ -----------
  Mean age (range)               
  60 (30--85)                    
  Gender                         
  Male                           92 (74.2)
  Female                         32 (25.8)
  Ethnicity                      
  AfricanAmerican                34 (27.4)
  Caucasian                      54 (43.6)
  Hispanic                       9 (7.3)
  Asian                          2 (1.6)
  Other                          25 (20.2)
  Diabetes mellitus              
  Yes                            51 (41.1)
  No                             73 (58.9)
  Cirrhosis etiology             
  HCV                            48 (38.7)
  HBV                            6 (4.8)
  ASH                            12 (9.7)
  NASH                           12 (9.7)
  Mixed (viral, ASH, and NASH)   38 (30.7)
  Other                          8 (6.5)
  Mean tumor diameter (cm)       
  4.9±4.1                        
  Tumor diameter (cm)            
  ≤5                             87 (71.9)
  \>5                            34 (28.1)
  Total number of tumors         
  1                              59 (47.6)
  2                              27 (21.8)
  3                              10 (8.1)
  4                              5 (4.0)
  5                              1 (0.8)
  6                              3 (2.4)
  \>6                            19 (15.3)
  Within Milan criteria          
  Yes                            65 (52.4)
  No                             59 (47.6)
  AFP, median (IQR) (ng/ml)      
  13.1 (6.0--44.3)               
  AFP \>50 ng/ml                 
  No                             91 (76.5)
  Yes                            28 (23.5)
  ChildPugh class                
  A                              53 (42.7)
  B                              56 (45.2)
  C                              15 (12.1)
  BCLC stage                     
  Stages 0, A                    48 (38.7)
  Stage B                        33 (26.6)
  Stage C                        27 (21.8)
  Stage D                        16 (12.9)
  Locoregional therapy           
  Y90                            17 (13.7)
  Ablation                       41 (33.1)
  RFA                            38 (30.6)
  MWA                            3 (2.4)
  TACE                           51 (41.1)
  TACE/ablation                  15 (12.1)
  TACE/RFA                       14 (11.3)
  TACE/PEI                       1 (0.8)

HBV: Hepatitis B virus, HCV: Hepatitis C virus, ASH: Alcoholic steatohepatitis, NASH: Non-alcoholic steatohepatitis, AFP: Alpha-fetoprotein, IQR: Interquartile range, MWA: Microwave ablation, RFA: Radiofrequency ablation, PEI: Percutaneous ethanol injection, TACE: Transarterial chemoembolization, Y90: Yttrium-90, BCLC: Barcelona clinic of liver cancer, ethnicity other: Alaska Native, Native Hawaiian, unavailable, cirrhosis etiology other: Primary (*n*=1), cryptogenic (*n*=5), sarcoidosis (*n*=1), hemochromatosis (*n*=1)

Locoregional therapies {#S2_2}
----------------------

LRT was performed by board-certified interventional radiologists with 2--20 years attending experience. Treatment modality was determined based on the BCLC staging algorithm and discussion in multidisciplinary tumor board. Y90 radioembolization was reserved for patients with multifocal and/or infiltrative disease, macrovascular invasion, and total bilirubin of \<2.0 mg/dL. RFA under ultrasound (US) and CT guidance was performed using 14-gauge multi-tined electrodes (Starburst®, Angiodynamics, Inc. Latham, NY) per manufacturer protocol. Conventional TACE was performed as previously described.^\[[@ref11]\]^ Three thermal ablations were performed with microwave antennas (PR 15, NeuWave Medical, Madison, WI) per manufacturer protocol. For Y90 radioembolization, all patients underwent planning mesenteric angiography with Tc-99 macroaggregated albumin administration and predetermined dose of Y90 was administered at lobar (*n* = 16) or segmental level (*n* = 1) using SIR-Spheres® (*n* = 13) (SIRTex, Sydney, NSW) or Theraspheres® (BTG, London, England) (*n* = 4). For patients treated with TACE/ablation, ablation was performed within 24 h of TACE.

Radiological assessment {#S2_3}
-----------------------

Baseline contrast-enhanced multiphase CT (*n* = 74) or MR (*n* = 38) obtained within 1 month before LRT was assessed for arterial-phase hyperenhancement, venous or delayed phase washout, delayed capsular enhancement, macrovascular invasion, and tumor diameter as per Liver Imaging Reporting and Data System definitions.^\[[@ref12]\]^ Follow-up CT or MR images were prescribed 1 month after LRT and every 3 months thereafter to assess for residual tumor or recurrence. Tumor response and progression were determined according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) by board-certified radiologists with 4--9 years attending experience who were blinded to histological data.^\[[@ref13]\]^ Complete response (CR) and partial response (PR) were considered an objective response. For patients with more than one CT or MRI before LRT (*n* = 50), tumor volume doubling time was determined based on the Schwartz equation (\[T×log~2~\]/3 × \[log(M~1~)--log(M~0~)\]; where, T is the interval in days between two MR or CT studies, M0 is the 1^st^ time maximum diameter, M1 is the 2^nd^ time maximum diameter).^\[[@ref14]\]^ Median value of tumor volume doubling time was utilized to dichotomize the variable.^\[[@ref15]\]^

Histological analysis {#S2_4}
---------------------

Percutaneous biopsy specimens were obtained under US guidance with an 18-gauge core needle (BioPince™, Argon Medical Devices, Frisco, TX) and immediately fixed in formalin. Histological analysis was performed by a board- certified pathologist (G.G). Eight patients (6%) had two biopsied HCC; one tumor was randomly selected per patient for inclusion in statistical analysis to maintain the independence of analyzed observations. Histological grade was classified by the Edmondson-Steiner (ES) system:^\[[@ref1]\]^ Grade 1 (well differentiated), Grade 2 (moderately differentiated), Grade 3 (poorly differentiated), and Grade 4 (pleomorphism). ES grade of 3 or 4 was defined as high grade. Cytology was classified as usual, clear, sclerosing, sarcomatoid, pleomorphic, fibrolamellar, steatohepatitis, or inflammatory type; specimens containing two or more subtypes were classified as mixed type.^\[[@ref1]\]^ Cytology was further categorized into three groups: 100% clear cell, focal clear cell (combination of clear cell and other variants), and absence of clear-cell components.^\[[@ref8]\]^ Architectural subtypes were classified as trabecular, pseudoglandular, and solid and specimens containing two or more subtypes were classified as mixed.^\[[@ref1]\]^

Clinical outcomes {#S2_5}
-----------------

Primary outcome measures were time to progression (TTP) after LRT and transplant-free survival (TFS). TTP was defined as the time from LRT to the detection of progression on imaging by mRECIST. TFS was defined as time from LRT to death or last clinical encounter; patients were censored at time of OLT.

Statistical analysis {#S2_6}
--------------------

Statistical analysis was performed using Statistical Analysis System (SAS) (2013, version 9.4; SAS Institute, Cary, NC). The association between two measurements was assessed on univariate analysis and by binary or multinomial logistic regressions when one of the measures was dichotomized or separated into \>2 categories, respectively. To examine the impact of measurements on TTP and TFS, both univariate and stratified Cox proportional hazard models were fitted accordingly and Kaplan--Meier curves were created. Two- sided *P* \< 0.05 was considered statistically significant. A two- sided *P* = 0.05--0.10 was considered a statistical trend.

RESULTS {#S3}
=======

Baseline biopsy and imaging characteristics {#S3_1}
-------------------------------------------

Tumors were ES Grade 1 (*n* = 13, 10.6%), 2 (*n* = 94, 76.4%), or 3 (*n* = 16, 13%) \[[Table 2](#T2){ref-type="table"}\]. Twenty-four specimens (20.9%) were comprised entirely of clear cells, 23 (20%) with focal clear cell, and 68 (59.1%) contained no clear cells. Architectural subtypes were trabecular (*n* = 44, 37.6%), pseudoglandular (*n* = 31, 26.5%), and solid or mixed solid pattern (*n* = 20, 17.1%). Baseline CT and MR imaging features are summarized in [Table 2](#T2){ref-type="table"}. Median value of tumor volume doubling time was 155 days (interquartile range \[IQR\] 100--221 days).

###### 

Baseline biopsy and imaging characteristics.

                                    *n* (%)
  --------------------------------- ------------
  ES grade                          
  1                                 13 (10.6)
  2                                 94 (76.4)
  3                                 16 (13.0)
  4                                 0 (0)
  Cytologic variant                 
  Usual                             64 (55.7)
  Clear                             24 (20.9)
  Sclerosing                        1 (0.9)
  Inflammatory                      1 (0.9)
  Fibrolamellar                     0 (0)
  Pleomorphic                       0 (0)
  Steatohepatitis                   0 (0)
  Sarcomatoid                       0 (0)
  Mixed                             25 (21.7)
  Architecture subtypes             
  Trabecular                        44 (37.6)
  Pseudoglandular                   31 (26.5)
  Mixed trabecular                  22 (18.8)
  Solid and mixed solid             20 (17.1)
  Clearcell amount                  
  100%                              24 (20.9)
  Focal                             23 (20.0)
  None                              68 (59.1)
  Microvascular invasion            
  Yes                               5 (9.1)
  No                                50 (90.9)
  Arterial phase hyperenhancement   
  Yes                               81 (82.6)
  No                                17 (17.4)
  Infiltrative appearance           
  Yes                               17 (14.2)
  No                                103 (85.8)
  Washout                           
  Yes                               95 (85.6)
  No                                16 (14.4)
  Delayed capsular enhancement      
  Yes                               44 (39.6)
  No                                67 (60.4)
  Macrovascular invasion            
  Yes                               13 (10.7)
  No                                109 (89.3)

Cytology mixed=Combination of any variant type (usual, clear, sclerosing, etc.) Clear cell 100%=Only clear cell, clear cell focal=Combination of clear cell+other cytological subtype, none=Absence of clear cell. ES: Edmondson-Steiner

Baseline features associated with high ES grade and clear- cell cytology by univariate analysis {#S3_2}
-----------------------------------------------------------------------------------------------

High ES grade was associated with baseline α-fetoprotein (AFP) level \>50 ng/ml (OR 4.6, 95% confidence interval \[CI\] 1.5--13.9; *P* = 0.007), BCLC Stage C (OR 4.5, 95% CI 1.3--16.4; *P* = 0.02), tumor diameter \>5 cm (OR 3.1, 95% CI 1.1--9.0; *P* = 0.035), and infiltrative appearance (OR 5.0, 95% CI 1.5--16.2; *P* = 0.0007) \[[Table 3](#T3){ref-type="table"}\]. There was a trend toward shorter tumor volume doubling time (\<155 days) with high ES grade (*P* = 0.09). About 100% clear-cell cytological variant was associated with non-viral cirrhosis (OR 5.3, 95% CI 1.6-- 17.2; *P* = 0.005) and both 100% clear cell and focal clear cell were associated solid architectural subtype (OR 6.3, 95% CI 1.8--21.9; *P* = 0.004 and OR 5.5, 95% CI 1.5--19.7; *P* = 0.009, respectively). Atypical contrast enhancement (lacking arterial-phase hyperenhancement or washout) was associated with 100% clear cell (OR 3.1, 95% CI 1.0--9.3; *P* = 0.046) but not with focal clear cell (OR 1.6, 95% CI 0.5--5.0; *P* = 0.44) in comparison to complete absence of clear cells. A trend was observed of clear-cell HCC being associated with lack of arterial-phase hyperenhancement (OR 3.2, 95% CI 0.9--11.1; *P* = 0.07) and comorbid diabetes mellitus (OR 2.6, 95% CI 1.0--6.7, *P* = 0.05). Clear-cell HCC was not associated with high tumor volume doubling time (OR 0.5, 95% CI 0.1--2.5, *P* = 0.39).

###### 

Histological associations with baseline characteristics by univariate analysis.

                                   ES grade high versus low   100% clear cell versus none   Focal clear cell versus none                      
  -------------------------------- -------------------------- ----------------------------- ------------------------------ ----------- ------ ----------
  Age                              1.0                        *P*=0.25                      1.0                            *P*=0.80    1.03   *P*=0.27
  Gender                                                                                                                                      
  Male                             1.0                                                      1.0                                        1.0    
  Female                           0.4                        *P*=0.26                      1.1                            *P*=0.79    1.2    *P*=0.71
  Ethnicity                                                                                                                                   
  American                         1.0                                                      1.0                                        1.0    
  Caucasian                        1.5                        *P*=0.59                      1.2                            *P*=0.69    1.6    *P*=0.44
  Other                            1.9                        *P*=0.37                      0.8                            *P*=0.78    1.6    *P*=0.46
  DM                                                                                                                                          
  No                               1.0                                                      1.0                                        1.0    
  Yes                              1.5                        *P*=0.41                      2.6                            *P*=0.05    1.4    *P*=0.48
  Cirrhosis etiology                                                                                                                          
  HCV                              1.0                                                      1.0                                        1.0    
  HBV                              1.5                        *P*=0.70                      0.0                            *P*=1.0     0.6    *P*=0.59
  ASH                              1.3                        *P*=0.74                      5.0                            *P*=0.05    0.9    *P*=0.92
  NASH                             0.8                        *P*=0.81                      7.5                            *P*\<0.05   0.6    *P*=0.59
  Mixed                            0.7                        *P*=0.61                      3.0                            *P*=0.10    0.8    *P*=0.73
  Other                            1.1                        *P*=0.92                      11.3                           *P*\<0.05   2.7    *P*=0.34
  Viral cirrhosis                                                                                                                             
  Yes                              1.0                                                      1.0                                        1.0    
  No                               0.8                        *P*=0.59                      5.3                            *P*\<0.01   1.0    *P*=0.95
  AFP \>50 ng/ml                                                                                                                              
  No                               1.0                                                      1.0                                        1.0    
  Yes                              4.6                        *P*\<0.01                     0.5                            *P*=0.30    1.5    *P*=0.49
  ChildPugh class                                                                                                                             
  A                                1.0                                                      1.0                                        1.0    
  B                                0.4                        *P*=0.09                      0.7                            *P*=0.43    0.4    *P*=0.09
  C                                0.1                        *P*=0.16                      0.8                            *P*=0.71    0.2    *P*=0.14
  BCLC stage                                                                                                                                  
  0, A                             1.0                                                      1.0                                        1.0    
  B                                1.5                        *P*=0.57                      1.5                            *P*=0.52    1.1    *P*=0.83
  C                                4.5                        *P*\<0.02                     1.4                            *P*=0.63    0.3    *P*=0.15
  D                                0.3                        *P*=0.44                      1.0                            *P*=0.98    0.2    *P*=0.18
  Tumor diameter                                                                                                                              
  ≤5 cm                            1.0                                                      1.0                                        1.0    
  \>5 cm                           3.1                        *P*\<0.05                     1.1                            *P*=0.85    1.5    *P*=0.49
  Within Milan criteria                                                                                                                       
  Yes                              1.0                                                      1.0                                        1.0    
  No                               2.0                        *P*=0.21                      0.8                            *P*=0.56    0.7    *P*=0.44
  Arterialphase hyperenhancement                                                                                                              
  Yes                              1.0                                                      1.0                                        1.0    
  No                               0.7                        *P*=0.69                      3.2                            *P*=0.07    1.8    *P*=0.38
  Washout                                                                                                                                     
  No                               1.0                                                      1.0                                        1.0    
  Yes                              1.7                        *P*=0.56                      0.8                            *P*=0.75    1.1    *P*=0.86
  Delayed capsular enhancement                                                                                                                
  No                               1.0                                                      1.0                                               
  Yes                              2.2                        *P*=0.17                      1.0                            *P*=0.95    1.8    *P*=0.24
  Enhancement pattern                                                                                                                         
  Typical                          1.0                                                      1.0                                        1.0    
  Atypical                         0.4                        *P=*0.33                      3.1                            *P\<*0.05   1.6    *P=0.44*
  Macrovascular invasion                                                                                                                      
  No                               1.0                                                      1.0                                        1.0    
  Yes                              2.4                        *P*=0.22                      0.7                            *P*=0.63    0.7    *P*=0.66
  Infiltrative appearance                                                                                                                     
  No                               1.0                                                      1.0                                        1.0    
  Yes                              5.0                        *P*\<0.01                     1.2                            *P*=0.84    1.2    *P*=0.79
  TVDT \>155 days                                                                                                                             
  No                               1.0                                                      1.0                                        1.0    
  Yes                              0.2                        *P*=0.09                      0.5                            *P*=0.39    2.0    *P*=0.35

Age: Age at LRT, DM: Diabetes mellitus, ethnicity other: Hispanic, Asian, Alaska Native, Native Hawaiian, unavailable, HBV: Hepatitis B virus, HCV: Hepatitis C virus, ASH: Alcoholic steatohepatitis, NASH: Non-alcoholic steatohepatitis, BCLC: Barcelona clinic of liver cancer, Typical enhancement pattern: Presence of arterial-phase hyperenhancement and washout, TVDT: Tumor volume doubling time, LRT: Locoregional therapy, ES: Edmondson-Steiner, OR: Objective response

Treatment response {#S3_3}
------------------

LRT achieved an objective response in 80 (75.4%) of the 106 tumors, in which follow-up imaging was available. High ES grade was not associated with objective response after LRT (OR 2.5, 95% CI 0.7--8.4; *P* = 0.15) by univariate analysis. The presence of 100% clear cell (OR 1.1, 95% CI 0.36--3.36; *P* = 0.87) or focal clear cell (OR 1.4, 95% CI 0.5--4.0; *P* = 0.57) on biopsy was not associated with objective response to LRT.

TTP and TFS by univariate and stratified analysis {#S3_4}
-------------------------------------------------

Median TTP was 178 days (IQR 81--311 days), with overall disease progression rate of 59.8% with median follow-up of 183 days (range: 12--1799 days).

On univariate analysis \[[Table 4](#T4){ref-type="table"}\], tumor burden exceeding Milan criteria (hazard ratio \[HR\] 2.6, 95% CI 1.6--4.4; *P* \< 0.001), baseline serum AFP level \>50 ng/ml (HR 2.5, 95% CI 1.4--4.4; *P* = 0.002), BCLC Stage B (HR 3.0, 95% CI 1.6--5.7; *P* \< 0.001), infiltrative appearance (HR 2.4, 95% CI 1.2--4.8; *P* = 0.01), and macrovascular invasion (HR 2.9, 95% CI 1.4--6.2; *P* = 0.006) were associated with disease progression. A trend was observed of a higher hazard of progression in tumors with microvascular invasion (HR 2.5, 95% CI 0.9--6.9; *P* = 0.08). High ES grade (HR 1.5, 95% CI 0.7--3.1; *P* = 0.33) \[[Figure 1a](#F1){ref-type="fig"}\] and 100% clear-cell variant (HR 1.4, 95% CI 0.8--2.6; *P* = 0.28) \[[Figure 2a](#F2){ref-type="fig"}\] were not associated with disease progression by univariate analysis. High ES grade or 100% clear cell also were not associated with progression when stratified by LRT modality or BCLC stage \[[Supplemental Table 1](#Supp1){ref-type="supplementary-material"}\].

###### 

Time to progression and transplant-free survival by Univariate analysis.

                                    TTP    TFS                 
  --------------------------------- ------ ------------ ------ ------------
  Age                               0.97   *P*\<0.05    1.0    *P*=0.79
  Gender                                                       
  Male                              1.0                 1.0    
  Female                            0.7    *P*=0.18     1.0    *P*=0.93
  Ethnicity                                                    
  African-American                  1.0                 1.0    
  Caucasian                         1.2    *P*=0.64     1.5    *P*=0.31
  Other                             0.7    *P*=0.35     0.9    *P*=0.78
  DM                                                           
  No                                1.0                 1.0    
  Yes                               0.7    *P*=0.19     0.9    *P*=0.78
  Cirrhosis etiology                                           
  HCV                               1.0                        
  HBV                               1.5    *P*=0.45     0.7    *P*=0.68
  ASH                               0.8    *P*=0.52     0.5    *P*=0.33
  NASH                              0.4    *P*=0.11     0.6    *P*=0.42
  Mixed                             1.0    *P*=0.92     1.00   *P*=0.99
  Other                             1.6    *P*=0.36     0.7    *P*=0.59
  Tumor diameter (cm)                                          
  ≤5                                1.0                        
  \>5                               1.7    *P*=0.06     2.0    *P*\<0.05
  Within Milan criteria                                        
  Yes                               1.0                 1.0    
  No                                2.6    *P*\<0.001   3.1    *P*\<0.001
  AFP \>50                                                     
  No                                1.0                 1.0    
  Yes                               2.5    *P*\<0.005   1.4    *P*=0.36
  ChildPugh class                                              
  A                                 1.0                 1.0    
  B                                 1.5    *P*=0.14     1.3    *P*=0.41
  C                                 2.1    *P*=0.13     2.9    *P*\<0.05
  BCLC stage                                                   
  0/A                               1.0                 1.0    
  B                                 3.0    *P*\<0.001   3.9    *P*\<0.005
  C                                 1.6    *P*=0.15     2.9    *P*\<0.05
  D                                 2.5    *P*=0.06     5.2    *P*\<0.005
  ES grade                                                     
  Low                               1.0                 1.0    
  High                              1.5    *P*=0.33     1.0    *P*=0.96
  Architecture subtypes                                        
  Trabecular                        1.0                 1.0    
  Mixed trabecular                  1.3    *P*=0.49     0.7    *P*=0.50
  Pseudoglandular                   1.0    *P*=0.89     1.3    *P*=0.55
  Solid and mixed solid             1.2    *P*=0.64     1.5    *P*=0.37
  Clearcell amount                                             
  None                              1.0                 1.0    
  Focal                             1.0    *P*=0.91     1.0    *P*=0.97
  100%                              1.4    *P*=0.28     1.0    *P*=0.95
  Microvascular invasion                                       
  No                                1.0                 1.0    
  Yes                               2.5    *P*=0.08     1.6    *P*=0.47
  Arterial phase hyperenhancement                              
  Yes                               1.0                 1.0    
  No                                0.7    *P*=0.19     1.1    *P*=0.75
  Infiltrative HCC                                             
  No                                1.0                 1.0    
  Yes                               2.4    *P*\<0.05    1.7    *P*=0.30
  Venous phase washout                                         
  No                                1.0                 1.0    
  Yes                               1.6    *P*=0.18     1.5    *P*=0.41
  Macrovascular invasion                                       
  No                                1.0                 1.0    
  Yes                               2.9    *P*\<0.01    3.0    *P*\<0.05
  Delayed capsular enhancement                                 
  No                                1.0                 1.0    
  Yes                               1.1    *P*=0.81     0.7    *P*=0.37
  OR after the first LRT                                       
  Yes                               1.0                 1.0    
  No                                2.3    *P*\<0.005   2.1    *P*\<0.05
  OR after all LRTs                                            
  Yes                               1.0                        
  No                                2.7    *P*\<0.001   2.4    *P*\<0.05
  Progression within 100 days                                  
  No                                \-                  1.0    
  Yes                               \-     \-           5.9    *P*\<0.001

TTP: Time to progression, TFS: Transplantfree survival, HBV: HepatitiB virus, HCV: Hepatitis C virus, ASH: Alcoholic steatohepatitis, NASH: Nonalcoholic steatohepatitis, ethnicity other: Alaska native, Native Hawaiian, unavailable, cirrhosis etiology other: Primary, cryptogenic, sarcoidosis, DM: Diabetes mellitus, BCLC: Barcelona clinicliver cancer, ES grade: EdmondsonSteiner grade, LRT: Locoregional therapy, OR: Objective response

![(a) Time to progression by Edmondson-Steiner (ES) grade after locoregional therapy. Kaplan--Meier curves of time to progression in patients with hepatocellular carcinoma of high ES grade (*n* = 13, median 118 days) or low ES grade (*n* = 93, median 182 days) treated with locoregional therapy. (b) Transplant-free survival (TFS) by ES grade after locoregional therapy. Kaplan--Meier curves of TFS in patients with hepatocellular carcinoma of high ES grade (*n* = 16, median 346 days) or low ES grade (*n* = 107, median 322 days) treated with locoregional therapy.](JCIS-9-52-g001){#F1}

![(a) Time to progression by clear-cell cytological composition. Kaplan--Meier curves of time to progression in patients with hepatocellular carcinoma (HCC) comprised 100% (*n* = 22, median 223 days), focal (*n* = 22, median 155 days), no (*n* = 55, median 178 days) clear cells treated with locoregional therapies. (b) Transplant-free survival by clear-cell cytological composition. Kaplan--Meier curves of TFS in patients with HCC comprised 100% (*n* = 24, median 350 days), focal (*n* = 23, median 429 days), no (*n* = 68, median 315 days) clear cells treated with locoregional therapies.](JCIS-9-52-g002){#F2}

Median TFS was 329 days (IQR 184--660 days). At the conclusion of the study period, 58 (47%) were alive, 40 (32%) were deceased, and 26 (21%) had undergone orthotopic liver transplant.

Decreased TFS was observed with baseline tumor diameter \>5 cm (HR 2.0, 95% CI 1.0--3.8; *P* = 0.05), tumor burden exceeding Milan criteria (HR 3.1, 95% CI 1.6--6.0; *P* = 0.001), CP Class C (HR 2.9, 95% CI 1.1--7.6; *P* = 0.03), BCLC Stage B (HR 3.9, 95% CI 1.7--9.0; *P* = 0.002), Stage C (HR 2.9, 95% CI 1.2--6.9; *P* = 0.02), Stage D (HR 5.2, 95% CI 1.8--15.0; *P* = 0.002), and macrovascular invasion (HR 3.0, 95% CI 1.2--7.9; *P* = 0.02) \[[Table 4](#T4){ref-type="table"}\]. In addition, stable or progressive disease after LRT was associated with lower TFS (HR 2.4, 95% CI 1.2--4.9; *P* = 0.02).

High ES grade (HR 1.0, 95% CI 0.3--2.8, *P* = 0.96) and 100% clear-cell variant (HR 1.02, 95% CI 0.5--2.2, *P* = 0.95) were not associated with TFS on univariate analysis \[[Figures 1b](#F1){ref-type="fig"} and [2b](#F1){ref-type="fig"}\]. High ES grade and 100% clear cell also were not associated with survival stratified by LRT modality or BCLC stage \[[Supplemental Table 1](#Supp1){ref-type="supplementary-material"}\]. When stratified by BCLC stage, there was a trend toward longer TFS with 100% clear cell in comparison to no clear cell in BCLC Stage B patients (HR 3.2, 95% CI 0.9--11.5; *P* = 0.08).

DISCUSSION {#S4}
==========

The baseline histological features of HCC underlying clinical presentation, radiologic features, and clinical outcomes following LRT are not fully understood. Prior studies that have demonstrated an association between histological subtype of HCC on recurrence and survival after resection, RFA, and transplant predominantly represent early-stage disease and histological assessment on surgical resection specimens or explant.^\[[@ref2]-[@ref5]\]^ In this study, histological information was assessed on percutaneous biopsy before LRT, and most patients (61%) were BCLC Stage B or greater. High tumor grade was significantly associated with aggressive tumor features such as large tumor diameter, elevated baseline serum AFP, and infiltrative appearance. In addition, the clear-cell variant was significantly associated with non-viral etiologies of cirrhosis and atypical contrast enhancement patterns on CT or MR images. While these findings suggest that tumor grade and cytological subtype in part underlie differences in baseline clinical and imaging features, such conventional histological information on percutaneous biopsy did not impart additional prognostic information from tumor stage and high-risk imaging features.^\[[@ref16]\]^

High ES has been associated with lack of objective response after drug-eluting embolic TACE in a retrospective cohort study of 93 patients who subsequently underwent OLT; however, the majority of patients were early stage, and histological differentiation was determined after TACE on explant.^\[[@ref5]\]^ In this study, no association was observed between high ES grade on percutaneous biopsy before LRT and objective response (OR 2.3, 95% CI 0.7--7.4; *P* = 0.15), suggesting that the predictive value of ES grade on post- therapy explant cannot be extrapolated to percutaneous biopsy specimens before LRT or patient populations with intermediate- or advanced-stage disease.

Poor histologic differentiation was associated with tumor diameter \>5 cm, infiltrative appearance, and elevated serum AFP, supportive of prior studies. AFP is considered to be secreted by dedifferentiated HCC,^\[[@ref17]\]^ and infiltrative appearance on imaging is known to be associated with higher AFP levels and worse survival after intra-arterial therapy.^\[[@ref18]\]^ While tumor size, infiltrative appearance, and elevated AFP were associated with reduced TTP and TFS in this cohort, no such association was observed with histological features on univariate or stratified analysis. The predictive value of histologic differentiation on prognosis was limited by the fact that 70% of tumors with elevated AFP (\>50 ng/ml), 75% of infiltrative HCC tumors, and 76% of tumors \>5 cm were histologically low grade on percutaneous biopsy in this study. This is consistent with a retrospective study of 63 patients showing that tumor grade and microvascular invasion did not predict clinical response or overall survival after transarterial embolization or TACE in 50 patients with prior percutaneous core biopsy.^\[[@ref19]\]^ While poor tumor differentiation has been associated with local tumor progression in a study of 95 BCLC Stage 0/A patients treated with RFA, these findings are confounded by high-grade tumors being larger than low-grade tumors in the cohort and more frequent use of internally cooled electrodes with a higher- powered generator in the low-grade group.^\[[@ref4]\]^

Clear-cell HCC is distinguished from other variants by clear cytoplasm attributed to increased glycogen or lipid contents secondary to metabolic changes.^\[[@ref9]\]^ Such morphologic and metabolic changes may result from differential oncogenic process between chronic viral hepatitis and non-viral etiologies of cirrhosis such as alcohol and metabolic syndrome.^\[[@ref20]\]^ Furthermore, clear-cell variant of HCC is known to have decreased number of intratumoral arteries in association with fatty changes; this is supportive of its association with atypical enhancement on CT or MRI in this study.^\[[@ref21]\]^ A significant association was observed between clear-cell variants and the solid architectural subtype, but its biological and clinical significance remains to be determined in future study.

While poor tumor differentiation is associated with recurrence and poor survival after OLT or surgical resection,^\[[@ref2],[@ref3]\]^ the impact of clear-cell HCC on prognosis is controversial: Some studies suggest that clear-cell variant is associated with longer overall survival,^\[[@ref6]-[@ref8]\]^ while other studies found similar survival between clear and non-clear- cell variant tumors after surgical resection.^\[[@ref9],[@ref10]\]^ It is postulated that longer survival in clear-cell variant is associated with relatively low histological grade and capsule formation that are favorable for surgery.^\[[@ref7]\]^ However, neither tumor grade nor clear-cell variant of HCC was associated with disease progression or TFS in our cohort after LRT.

Microvascular invasion on explant is strongly correlated with recurrence after OLT or surgical resection.^\[[@ref22],[@ref23]\]^ In this study, a trend was observed toward a higher hazard of progression in tumors with microvascular invasion but not TFS. The lack of observed association in this study may be due to different methods to acquire HCC specimens: Percutaneous biopsy versus explant or surgical resection. In this cohort, only 13% of tumors were high ES grade and 9.1% demonstrated microvascular invasion on percutaneous core biopsy. In contrast, a study comprised 76% BCLC 0/A patients reported 53% were high ES grade and 51% had microvascular invasion on resection.^\[[@ref24]\]^ Thus, the lack of observed association between ES grade and microvascular invasion in the current study with treatment response, TTP, and TFS may be attributable to the intrinsic limitation of percutaneous biopsy, where high-grade tumors are frequently misclassified as low grade due to sampling error of heterogeneous tumors. Prior studies have demonstrated that percutaneous biopsy underestimates tumor grade and microvascular invasion compared to resection.^\[[@ref25]\]^

This study demonstrates that histological analysis of tumor grade can stratify HCC given its association with aggressive clinical and radiologic features. However, this study also supports the current practice of deferring conventional histological analysis before LRT in tumors diagnosed by imaging criteria^\[[@ref12]\]^ given the lack of independent prognostic information imparted by tumor grade and microvascular invasion on percutaneous biopsy. Although the prognostic value of conventional histological analysis before LRT may be limited, immunohistochemistry and genomic sequencing analysis of percutaneous biopsy specimens are under active investigation and percutaneous biopsy may yet prove critical to treatment allocation in the emerging era of precision medicine. Certain genetic mutations involved in Wnt/β- catenin and hypoxia stress response have been associated with objective response after transarterial embolization in primary and metastatic liver tumors.^\[[@ref26]\]^ Furthermore, high expression of programmed death ligand-1 on resected HCC specimens is associated with poor tumor differentiation, elevated AFP, microvascular invasion,^\[[@ref24]\]^ and poor disease- free survival and overall survival.^\[27,28\]^

Our study bears several limitations. First, the retrospective single-institution design renders potential sampling bias in our cohort. Although the majority of tumors in this study demonstrated typical arterial-phase hyperenhancement and washout, a retrospective study of percutaneously biopsied HCC study will be inevitably enriched with HCC with non-diagnostic imaging features. Our cohort consisted of predominantly Caucasian and African-American patients with viral etiologies of HCC, and extrapolation of findings to other populations should be performed with caution. The relatively low number of patients with high ES grade (13%) in this cohort might have increased our susceptibility to a type II error. Similarly, while our study is unique in including BCLC B, C, and D patients, the variability in BCLC stage and LRT modality may have introduced confounding and reduced our ability to observe associations between histological features and outcomes. However, numerous tumor and clinical features, such as tumor size and BCLC stage, were significantly associated with TFS in this study; although a larger study may detect an association between histologic features on percutaneous biopsy on LRT outcomes, it is unlikely that histological features are superior prognostic indicators compared to macroscopic tumor features such as size and portal vein invasion, and clinical factors including BCLC stage. As discussed, studies utilizing percutaneous biopsy specimens are prone to histological misclassification bias due to non-representative tissue sampling of histologically heterogeneous tumors.

CONCLUSION {#S5}
==========

High histologic grade of HCC on percutaneous biopsy is associated with poor prognostic indicators such as larger tumors, infiltrative appearance, and advanced BCLC stage. The clear-cell variant of HCC was associated with non-viral cirrhosis, and the paucity of arteries in this subtype may underlie the atypical enhancement associated with these tumors. Percutaneous biopsy, therefore, may be used to diagnose HCC, but histological stratification did not provide independent prognostic information. The findings support deferral of percutaneous biopsy and histological assessment of HCC diagnosed by imaging criteria before LRT.
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